James Zidar is a Cardiology physician affiliated with Rex Hospital. OpenAlex indexes 82 publications with 4,576 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JanssenProgram year202515 paymentsResearch$35,110
- Shockwave MedicalProgram year20252 paymentsResearch$19,959
- Boston ScientificProgram year20251 paymentResearch$18,850
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
78.3%Beta blocker19.1%Metoprolol Succinate67%Metoprolol Tartrate14%Carvedilol13%Atenolol4%Sotalol2%Labetalol Hcl1%Part D<11 patientsStatin14.5%Rosuvastatin Calcium44%Atorvastatin Calcium40%Pravastatin Sodium10%Simvastatin6%Part D≥115 patients+ 15 more classes in this area
Blood & clotting
18.8%Factor Xa inhibitor9.7%Eliquis84%Xarelto17%Part D≥94 patientsP2Y12 inhibitor8.1%Clopidogrel85%Prasugrel Hcl8%Brilinta7%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
2.1%Proton pump inhibitor1.3%Pantoprazole Sodium83%Omeprazole17%Part D<11 patientsPotassium supplement0.6%Potassium Chloride100%Part D≥12 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy
Journal of the Society for Cardiovascular Angiography & Interventions
2022 - Safety and Efficacy of the Supreme Biodegradable Polymer Sirolimus-Eluting Stent in Patients With Diabetes Mellitus
Journal of the Society for Cardiovascular Angiography & Interventions
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Tibor Becske, MD
Rex Hospital
Ravish Sachar, MD
Rex Hospital
Jeremiah Boles, MD
Rex Hospital
Martyn Knowles, MD
Rex Hospital
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Martin Leon, MD
Columbia University Irving Medical Center
Gregg Fonarow, MD
Ronald Reagan UCLA Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”